Bempedoic acid – a new drug in lipid-lowering therapy

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The clinical significance of lipid-lowering therapy in reducing the risk of atherosclerotic cardiovascular disease (CVD) and mortality has been proven. However, the achievement of target levels of cholesterol and its fractions in real practice is not ensured, there are problems with the tolerability of standard drugs (statins), often the use of additional lipid-lowering agents (ezetimibe, PCSK9 inhibitors) is required. In February 2020, the FDA approved a new drug, bempedoic acid (BA), recommended in the US and the European Union (EU) as an adjuvant to maximally tolerated statin therapy to lower low-density lipoprotein cholesterol in patients with atherosclerotic CVD and familial hypercholesterolemia, as well as in cases of intolerance or contraindications to the use of statins or in combination with ezetinib. The article presents data on the mechanism of action and clinical pharmacology of the drug, the results of 2nd and 3rd phase clinical trials (a series of CLEAR studies) to assess the safety and lipid-lowering efficacy in different categories of patients and modern meta-analyzes, as well as the results of a recent large study CLEAR Outcomes to assess major cardiovascular outcomes with BA. The place of BA in lipid-lowering therapy in patients with atherosclerotic CVD is also discussed.

Full Text

Restricted Access

About the authors

Marina V. Leonova

Interregional Public Organization of the Association of Clinical Pharmacologists (Moscow branch)

Author for correspondence.
Email: anti23@mail.ru
ORCID iD: 0000-0001-8228-1114
SPIN-code: 3281-7884

Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Natural Sciences, Member of the Interregional Public Organization of the Association of Clinical Pharmacologists

Russian Federation, Moscow

References

  1. Baigent C., Keech A., Kearney P.M., et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78. doi: 10.1016/S0140-6736(05)67394-1.
  2. Baigent C., Blackwell L., Emberson J., et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. doi: 10.1016/S0140-6736(10)61350-5.
  3. Bruckert E., Parhofer K.G., Gonzalez-Juanatey J.R., et al. Proportion of high-risk/very high-risk patients in Europe with low-density lipoprotein cholesterol at target according to European guidelines: a systematic review. Adv Ther. 2020;37(5):1724–36. doi: 10.1007/s12325-020-01285-2.
  4. Grundy S.M., Stone N.J., Bailey A.L., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285–350. Doi: 10.1016/ j.jacc.2018.11.003.
  5. Mach F., Baigent C., Catapano A.L., et al.; ESC Scientific dDocument Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. doi: 10.1093/eurheartj/ehz455.
  6. Markham A. Bempedoic Acid: First Approval. Drugs. 2020;80(7):747–53. doi: 10.1007/s40265-020-01308-w.
  7. Agarwala A., Goldberg A.C. Bempedoic acid: a promising novel agent for LDL-C lowering. Future Cardiol. 2020;16(5):361–71. doi: 10.2217/fca-2020-0016.
  8. Burke A.C., Telford D.E., Huff M.W. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 2019;30(1):1–9. doi: 10.1097/MOL.0000000000000565.
  9. Pinkosky S.L., Newton R.S., Day E.A., et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:13457. doi: 10.1038/ncomms13457.
  10. Ballantyne C.M., Bays H., Catapano A.L., et al. Role of bempedoic acid in clinical practice. Cardiovasc. Drugs Ther. 2021;35(4):853–64. doi: 10.1007/s10557-021-07147-5.
  11. Ballantyne C.M., Davidson M.H., Macdougall D.E., et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013;62(13):1154–62. doi: 10.1016/j.jacc.2013.05.050.
  12. Thompson P.D., Rubino J., Janik M.J., et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015;9(3):295–304. doi: 10.1016/j.jacl.2015.03.003.
  13. A study of the safety, pharmacokinetic drug interaction and efficacy of ETC-1002 and atorvastatin in subjects with hypercholesterolemia (2019). URL: https://clinicaltrials.gov/ct2/show/NCT01779453.
  14. Ballantyne C.M., McKenney J.M., MacDougall D.E., et al. Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy. Am J Cardiol. 2016;117(12):1928–33. doi: 10.1016/j.amjcard.2016.03.043.
  15. Lalwani N.D., Hanselman J.C., Macdougall D.E., et al. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: a randomized placebo-controlled trial. J Clin Lipidol. 2019;13(2):568–79. doi: 10.1016/j.jacl.2019.05.003.
  16. Thompson P.D., Macdougall D.E., Newton R.S., et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016;10(3):556–67. doi: 10.1016/j.jacl.2015.12.025.
  17. Rubino J., MacDougall D.E., Sterling L.R., et al. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial. Atherosclerosis. 2021;320:122–28. doi: 10.1016/j.atherosclerosis.2020.12.023.
  18. Evaluation of the efficacy and safety of bempedoic acid (ETC-1002) 180mg when added to PCSK9 inhibitor therapy (2019). URL: https://clinicaltrials.gov/ct2/show/NCT03193047.
  19. Gutierrez M.J., Rosenberg N.L., Macdougall D.E., et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and Type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014;34(3):676–83. doi: 10.1161/ATVBAHA.113.302677.
  20. Evaluation of ETC-1002 in patients with hypercholesterolemia and hypertension (2019). URL: https://clinicaltrials.gov/ct2/show/NCT02178098
  21. Ray K.K., Bays H.E., Catapano A.L., et al.; CLEAR Harmony Trial. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022–32. doi: 10.1056/NEJMoa1803917.
  22. Laufs U., Banach M., Mancini G.B.J., et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662. doi: 10.1161/JAHA.118.011662.
  23. Ballantyne C.M., Banach M., Mancini G.B.J., et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195–203. doi: 10.1016/j.atherosclerosis.2018.06.002.
  24. Goldberg A.C., Leiter L.A., Stroes E.S.G., et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: The CLEAR Wisdom randomized clinical trial. JAMA. 2019;322(18):1780–88. doi: 10.1001/jama.2019.16585.
  25. Cicero A.F.G., Fogacci F., Hernandez A.V., Banach M.; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert Panel (ILEP). Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis. PLoS Med. 2020;17(7):e1003121. doi: 10.1371/journal.pmed.1003121.
  26. Lin Y., Parco C., Karathanos A., et al. Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis. BMJ. Open. 2022;12(2):e048893. doi: 10.1136/bmjopen-2021-048893.
  27. Bays H.E., Banach M., Catapano A.L., et al. Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials. J Clin Lipidol. 2020;14(5):649–59.e6. doi: 10.1016/j.jacl.2020.08.009.
  28. Preiss D., Seshasai S.R., Welsh P., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–64. doi: 10.1001/jama.2011.860.
  29. Leiter L.A., Banach M., Catapano A.L., et al. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials. Diab Obes Metab. 2022 Jan 3. doi: 10.1111/dom.14645.
  30. Shapiro M.D., Taub P.R., Louie M.J., et al. Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: pooled analysis of datafFrom four phase 3 clinical trials. medRxiv 2023.03.03.23286700. doi: 10.1101/2023.03.03.23286700.
  31. Nissen S.E., Lincoff A.M., Brennan D., et al. CLEAR Outcomes Investigators. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353–64. doi: 10.1056/NEJMoa2215024.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig.1.

Download (79KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies